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Abstract
Many antipsychotic drugs disrupt active components of maternal behavior such as pup approach, pup retrieval and nest
building at clinically relevant doses in postpartum female rats. However, the neurochemical mechanisms underlying such
a disruptive effect remain to be determined. This study examined the neurochemical mechanisms that mediate the disruptive effects of haloperidol (a typical antipsychotic) and clozapine (an atypical antipsychotic) on rat maternal behavior.
Postpartum rats were administered with haloperidol (0.2 mg/kg, sc) or clozapine (10.0 mg/kg, sc) together with either vehicle (saline or water), quinpirole (a selective dopamine D2/D3 agonist, 0.5 or 1.0 mg/kg, sc), or 2,5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-HT2A/2C agonist, 1.0 or 2.5 mg/kg, sc), and their maternal behaviors were tested at different
time points before and after drug administration. Haloperidol and clozapine treatment disrupted pup approach, pup retrieval, pup licking and nest building. Pretreatment of quinpirole, but not DOI, dose-dependently reversed the haloperidol-induced disruptions. In contrast, pretreatment of DOI, but not quinpirole, dose-dependently reversed the clozapineinduced disruptions. Quinpirole pretreatment even exacerbated the clozapine-induced disruption of pup retrieval and
nest building. These findings suggest a double dissociation mechanism underlying the disruption of haloperidol and clozapine on rat maternal behavior. Specifically, haloperidol disrupts maternal behavior primarily by blocking dopamine D2
receptors, whereas clozapine exerts its disruptive effect primarily by blocking the 5-HT2A/2C receptors. Our findings also
suggest that 5-HT receptors are involved in the mediation of rat maternal behavior.
Keywords: Haloperidol, Clozapine, Dopamine D2/D3 receptor, Quinpirole, 5-HT2A/2C receptor, DOI, Rat maternal
behavior
1. Introduction

as pup retrieval, pup licking and nest building (Li et al., 2004;
Stern and Taylor, 1991; Stern and Keer, 1999; Zhao and Li, 2009).
HAL causes a prolonged disruption (up to 6 h), whereas CLZ and
other atypical antipsychotics induce an early onset but transient
disruption (less than 6 h). Novel antipsychotics such as amisulpride and aripiprazole also exhibit a certain degree of inhibition
on active maternal responses in a dose-dependent fashion (Li et
al., 2005a). Chronic treatment with HAL or olanzapine via minipumps or repeated daily injections significantly inhibits rat active maternal responses as well (Li et al., 2005b). It seems that
antipsychotic-induced inhibition on pup retrieval, pup licking
and nest building may be an inherent feature of all currently
available antipsychotics (Li et al., 2004, 2005a; Silva et al., 2001;
Stern and Taylor, 1991; Stern and Keer, 1999; Zhao and Li, 2009).
Our recent work further identifies that sedation and suppression of maternal motivation are two important behavioral mechanisms underlying the disruptive effects of antipsychotic treatment on maternal behavior (Zhao and Li, 2009).
The present study investigated the neurochemical basis of
antipsychotic-induced disruptive effects on rat maternal behavior. For typical antipsychotics, it is generally assumed that
they disrupt maternal behavior by blocking dopamine D2 recep-

Maternal behavior in rats is a complex behavior that shares many
features with human mothering behavior (Fleming and Corter,
1988). It is naturally expressed for the first time with the birth of
the first litter. Within hours of parturition, the mother rat reconstructs the nest, retrieves the displaced pups, gathers them together in the nest site and adopts a nursing posture over the pups
to permit suckling (Dollinger et al., 1980; Rosenblatt and Lehrman, 1963). The mother rat (dam) continues to exhibit maternal
behavior (pup licking, pup retrieval, nest building and nursing)
over the subsequent 3-week period, although as the pups mature,
the intensity and quality of her behavior changes (Galef, 1981;
Rosenblatt and Lehrman, 1963).
In recent years, we have used the rat maternal behavior as an
ecologically relevant model to investigate the behavioral mechanisms of action of antipsychotic drugs and attempted to capture the possible side effects of antipsychotic medications on
human parental behaviors. We and others have shown that clinically comparable doses of haloperidol (HAL), clozapine (CLZ),
risperidone and quetiapine (~ 50%–70% dopamine D2 occupancy) disrupt active components of rat maternal behavior, such
433
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tors because they are primarily dopamine D2 antagonists (Dragunow et al., 1990; Seeman et al., 1976), and because apomorphine, a dopamine receptor agonist, can reverse the inhibitory
effects of haloperidol (Giordano et al., 1990). However, solid evidence demonstrating that typical antipsychotics do act through
this specific D2 mechanism is still lacking. For atypical antipsychotics (e.g., clozapine, olanzapine), because they generally have
multiple-receptor binding profiles (Meltzer, 1989; Miyamoto et
al., 2005), it is hard to pinpoint their exact neurochemical mechanisms. Most atypical antipsychotics possess a much more potent antagonism on the 5-HT2 receptor in addition to relatively
weak antagonism on D2 receptor (Meltzer et al., 2003). It is thus
possible that the disruptive effects of atypical antipsychotics on
maternal behavior could be attributed to their action on D2 receptor alone (Kapur and Seeman, 2001) or to its dual action on
both 5-HT2 and D2 receptors (Meltzer et al., 1989a, 1989b) or on
other receptors.
In the present study, we administered quinpirole, a selective
D2/D3 dopaminergic receptor agonist or 2,5-dimethoxy-4-iodoamphetamine (DOI), a selective 5-HT2A/2C serotonergic receptor
agonist together with HAL (0.2 mg/kg) or CLZ (10.0 mg/kg) to
postpartum rats. We examined which of these two agonists was
able to reverse the disruptive effects induced by HAL or CLZ. We
hypothesized that quinpirole, but not DOI, would be able to reverse the HAL-induced disruption on maternal behavior and
may also be effective in alleviating the CLZ-induced disruption
to some extent. We had no prior conviction regarding the effect
of DOI due to lack of sufficient evidence in the literature on the
role of serotonin in maternal behavior (Numan and Insel, 2003).
2. Materials and methods
2.1. Subjects
Animals were naive pregnant female Sprague–Dawley rats (9–
12 weeks old at the start of pregnancy) purchased from Charles
River Inc. (Portage, MI). Upon arrival to our animal facility,
the rats were between gestational days 13–15. Each subject was
housed individually in 48.3 cm × 26.7 cm × 20.3 cm transparent
polycarbonate cage lined with aspen shavings in a colony on a
12-h light/dark cycle (lights on at 6:30 AM). All behavioral tests
were performed in the light phase between 9:00 AM and 4:00
PM. The colony was maintained under standard vivarium conditions with an ambient temperature of 23 °C, relative humidity of
55–60%. Standard laboratory rat chow and water were available
adlibitum. All animal procedures were approved by the University of Nebraska Institutional Animal Care and Use Committee.
2.2. Drugs and choices of doses
HAL (5.0 mg/ml ampoules, Sicor Pharmaceuticals, Inc, Irvine,
CA) was diluted with sterile water. CLZ (a gift from NIMH drug
supply program) was dissolved in 1.0% glacial acetic acid in distilled water. Quinpirole (QUI) and DOI (RBI-Sigma, Natick,
MA) were dissolved in 0.9% saline. HAL (0.2 mg/kg), CLZ
(10.0 mg/kg), QUI (0.5 or 1.0 mg/kg), DOI (1.0 or 2.5 mg/kg) and
vehicle (water or saline) were all administered subcutaneously
in a volume of 1.0 ml/kg body weight. Choices of drug doses for
HAL and CLZ were based on our previous studies showing that,
at these doses, HAL and CLZ effectively disrupt active maternal
behaviors in rats (Li et al., 2004; Zhao and Li, 2009). The doses
of QUI were chosen based on our preliminary study showing
that 1.0 mg/kg of QUI improved the HAL’s disruption on pup retrieval. DOI doses were chosen on the basis of reports showing
that DOI at these doses potentiates the effects of amphetamine
on dopamine release in the striatum, medial prefrontal cortex
and nucleus accumbens (Ichikawa and Meltzer, 1995; Kuroki et
al., 2003) and blocks the CLZ-induced dopamine release in the
medial prefrontal cortex (Ichikawa et al., 2001).

2.3. Basic experimental procedure
Starting 2 or 3 days prior to the first possible expected parturition date, the subjects were monitored every morning for signs
of parturition. Once the dam was found with pups in the morning (that day was designated as Day 1 postpartum), the mother
was transferred into a clean cage with wood shavings for bedding. Two shredded paper towels were also provided for nesting
material. The litter was culled to 8 pups (4 males and 4 females
with the most visible milk bands). Maternal behavior tests were
conducted on one day between Days 6 and 8 postpartum.
2.4. Maternal behavior test
The basic procedure was similar to what has been described in
Zhao and Li (2009). Using a laptop computer with an event recording program (JWatcher, http://www.jwatcher.ucla.edu/), we
recorded various components of maternal behavior in an 8-min
testing session at different time points before and after drug administration. Each test started by removing the 8 pups from the
dam and destroying the nest. Ten seconds later, the pups were
returned to the corner of the cage diagonal to the nest site or
dam sleeping corner. When the subject picked up a pup in her
mouth and carried it back to the nest site, it was referred to as
a successful pup retrieval. The total number of pups retrieved
was recorded. Approach latency was defined as the time taken
for mother rats to approach and sniff the pups from the reunion.
First and last pup retrieval latency was defined as the time
elapsed from the first pup approach to the retrieval of the first
and eighth pup into the nest, respectively. A score of 480 s was
assigned to non-responders who did not approach or retrieve
the testing pups at all. The occurrence of other behaviors was
also recorded, including pup nursing behavior (a rat positioning herself over the pups with legs splayed to accommodate the
pups, including hover, high and low crouching over postures),
pup licking (a female rat placing its tongue on the anogenital area and the rest of a pup’s body), nest building (a rat picking up nesting material in her mouth and transporting it back
to the nest site or pushing the material with her forepaws toward
the nest site). At the conclusion of the test, any unretrieved pups
were returned to the nest site.
2.4.1. Experiment 1. Effects of pretreatment with quinpirole or
DOI on haloperidol-induced maternal behavior deficits in rats
Forty-four postpartum rats were randomly assigned to one of the
following six groups: VEH+VEH (n = 4, sterile water or saline),
VEH+HAL (n = 8), QUI-0.5+HAL (n = 8), QUI-1.0+HAL (n = 8),
DOI-1.0+HAL (n = 8), and DOI-2.5+HAL (n = 8). On the drug
test day (1 day on either Postpartum Day 6, 7, or 8), all subjects
were tested 5 times at different time points before and after drug
administrations, with the first maternal behavior test starting at
30 min prior to the HAL or vehicle injection (i.e., baseline) and
the other tests occurring at 30, 60, 120 and 240 min after HAL
or vehicle injection. QUI, DOI or vehicle was injected s.c. twice
with the first injection at 10 min before and the second at 50 min
after the HAL or vehicle injection. We adopted such an injection strategy because our preliminary data showed that injection
of QUI at 10 min prior to the administration of HAL could optimally reverse its disruption on pup retrieval. Also, agonists were
injected twice separately on the basis of their relatively short duration of action and rapid peak plasma concentrations (Deutch
and Duman, 1996; Whitaker and Lindstrom, 1987).
2.4.2. Experiment 2. Effects of pretreatment with quinpirole or
DOI on clozapine-induced maternal behavior deficits in rats
The basic procedure was identical to that of Experiment 1 with
the exception that CLZ was tested in this experiment instead
of haloperidol. Forty-four postpartum rats were randomly assigned to one of the following six groups and their maternal be-
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haviors were tested: VEH+VEH (n = 4, sterile water or saline),
VEH+CLZ (n = 8), QUI-0.5+CLZ (n = 8), QUI-1.0+CLZ (n = 8),
DOI-1.0+CLZ (n = 8), and DOI-2.5+CLZ (n = 8).
2.5. Data analysis
With the exception of latency data, various measurements of
maternal behavior were expressed as mean ± SEM. To increase
statistical power, we combined the two vehicle control groups
from Experiments 1 and 2 into a single group since they did not
differ significantly on any measure (Independent-Samples T test
or Mann–Whitney U test, all ps > 0.10). Data were analyzed using a factorial repeated measures analysis of variance (ANOVA)
with the between-subjects factor being the treatment groups
(e.g. saline, HAL) and the within-subjects factor being test time
points (baseline, 30, 60, 120 and 240 min post-injection). Group
differences at different time points were further analyzed using
simple main effect test (one-way ANOVA) followed by Turkey’s
HSD post hoc tests where appropriate.
For the latency data, because they were not normally distributed (e.g. the cut-off time assigned 480 s for the latency data),
these data were expressed as median ± interquartile range. Nonparametric Kruskal–Wallis test was used for analyzing the differences among the treatment groups. Once the overall significant
effects were determined, two-group comparisons were performed using Mann–Whitney U test. A conventional two-tailed
level of significance at the 0.05 level was required.
3. Results
3.1. Experiment 1. Effects of pretreatment with QUI or DOI
on haloperidol-induced maternal behavior deficits
3.1.1. Haloperidol treatment disrupted various components of maternal behavior
Consistent with our previous findings (Li et al., 2004; Zhao and
Li, 2009), a single injection of HAL significantly disrupted various active components of maternal behavior (pup retrieval, pup
licking, nest building, but not pup nursing). Rats treated with
HAL took a much longer time to initiate contact with pups and
retrieve their pups into the nest sites (Table 1) and retrieved
fewer pups at the 30, 60, 120 and 240 min test points (Figure
1 and Figure 2A) (0.001 < all ps < 0.05) compared to the vehicle-treated rats. They also spent less time licking their pups at
the 30, 60 and 120 min test points and rebuilding the nest at the
30, 60, 120 and 240 min test points ( Figure 1 & Figure 2 B,C)
(0.001 < all ps < 0.05). However, HAL treatment had no significant effect on nursing activity ( Figure 1 & Figure 2D).
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3.1.2. QUI pretreatment dose-dependently improved the haloperidol-induced maternal behavior deficits
As can be seen in Table 1 and Figure 1A–C, both doses of QUI improved the HAL-induced deficits in pup approach, pup retrieval,
pup licking and nest building, as described below.
3.1.2.1. Latency to approach and retrieve pups. QUI shortened the HAL-induced increase in pup approach latency and
the first and last pup retrieval latencies (Table 1). Both 0.5 and
1.0 mg/kg doses of QUI were effective in facilitating the HALtreated dams to initiate contact with their pups and completely
restored such behavior to the normal level (e.g., VEH+VEH
group) across the testing period. For the pup retrieval latency, it
appeared that both doses of QUI shortened the time the HALtreated rats took to retrieve their first and last pups to the nest
site and reinstated the first pup retrieval to the normal level at
the 30, 120 and 240 min test points post-injection.
3.1.2.2. Number of pups retrieved. Both 0.5 and 1.0 mg/kg of
QUI increased the number of pups retrieved in the HAL-treated
rats and restored it to the normal level at certain time points of
testing. Repeated measures ANOVA revealed that there was a significant interaction between the treatment groups and time points
[F (20, 168) = 5.97, p < 0.001], a significant main effect of treatment
groups [F (5, 42) =26.30, p < 0.001], and a significant effect of time
points [F (4, 168) =35.22, p < 0.001]. One-way ANOVA and post hoc
tests showed that the QUI-0.5+HAL group was significantly different from the VEH+HAL group at the 30 and 120 min time points
(Figure 1A, p < 0.001 for 30 min, p = 0.022 for 120 min), whereas
the QUI-1.0+HAL group differed from the VEH+HAL group at the
30, 120 and 240 min test points (Figure 1A, p < 0.001 for 30 and
120 min, p = 0.014 for 240 min). Further analysis showed that the
reversing effect of 0.5 mg/kg of QUI reached the control level at
the 30 and 120 min test points while the 1.0 mg/kg of QUI restored
the CLZ-induced disruption to the normal level at the 30, 120 and
240 min test points when the two QUI+HAL groups were compared with the VEH+VEH control group (Figure 1A, all ps > 0.10). It
appears that the strongest reversal effect of QUI occurred 120 min
after HAL administration (Figure 1A).
3.1.2.3. Pup licking. QUI produced a reversing effect on HALinduced pup licking deficit. Repeated measures ANOVA revealed
a main effect of treatment groups [F (5, 42) = 4.56, p = 0.002], a
significant effect of test time points [F (4, 168) = 7.71, p < 0.001],
but no significant interaction between the two factors. One-way
ANOVA and post hoc tests showed that both QUI groups differed
significantly from the VEH+HAL group at the 120 min test point
(Figure 1B, p = 0.045 for QUI-0.5+HAL group, p = 0.042 for QUI1.0+HAL group). Further analysis showed that the reversing effect

Table 1. Effects of pretreatment with quinpirole or DOI on pup approach latency and pup retrieval latency in postpartum female rats treated with haloperidol or vehicle.
Groups

N

Approach latency (s) 			

		

Baseline 30 min

60 min

VEH+VEH
8
		
VEH+HAL
8
		
QUI-0.5+HAL 8
		
QUI-1.0+HAL 8
		
DOI-1.0+HAL 8
		
DOI-2.5+HAL 8
		

2.1
(2.0)
1.8
(0.9)
1.4
(0.8)
2.8
(4.1)
1.3
(0.7)
2.0
(5.9)

1.5
1.5
(1.2)
(0.8)
87.5a
45.4a
(311.7) (224.6)
3.4b
2.6b
(26.9) (5.6)
12.5b
7.7b
(78.1) (24.5)
115.7a 43.6a
(122.6) (52.2)
480.0a,b 278.6a
(169.4) (446.2)

1.2
(0.7)
15.6a
(106.9)
2.2b
(15.1)
2.8b
(7.4)
13.1a
(29.5)
49.3a
(107.8)

First pup retrieval latency (s) 		

120 min 240 min Baseline 30 min

1.9
(4.6)
23.2a
(135.1)
8.8b
(41.6)
5.6b
(14.2)
30.6a
(361.4)
81.9a
(216.1)

2.8
(87.0)
11.7
(100.8)
47.4
(89.6)
30.7
(84.1)
2.8
(189.40
3.1
(15.3)

2.0
(0.9)
480.0a
(0.0)
4.0b
(35.7)
4.3b
(12.0)
293.6a
(441.1)
480.0a
(0.0)

Last pup retrieval latency (s)

60 min

120 min 240 min Baseline 30 min

60 min

120 min 240 min

2.6
(1.4)
480.0a
(0.0)
480.0a
(357.8)
247.1a
(474.9)
480.0a
(0.0)
480.0a
(0.0)

2.1
(0.7)
480.0a
(0.0)
3.3b
(358.2)
3.1b
(2.0)
480.0a
(0.0)
480.0a
(0.0)

23.9
(7.7)
480.0a
(0.0)
480.0a
(241.2)
480.0a
(284.9)
480.0a
(0.0)
480.0a
(0.0)

21.7
(9.8)
480.0a
(0.0)
285.4a
(443.6)
145.9a,b
(104.0)
480.0a
(0.0)
480.0a
(0.0)

Data are represented as median ± interquartile range.
a. p < 0.05 relative to the VEH+VEH group; b. p < 0.05 relative to the VEH+HAL group

1.9
(0.5)
245.6a
(476.1)
3.3b
(358.4)
2.4b
(0.7)
65.2a
(476.8)
480.0a
(0.0)

38.3
(104.0)
112.4
(382.9)
141.0
(289.1)
152.3
(260.0)
179.7
(450.6)
69.6
(59.2)

22.6
(9.7)
480.0a
(0.0)
75.9a,b
(55.9)
105.7a,b
(417.8)
480.0a
(0.0)
480.0a
(0.0)

24.0
(14.4)
480.0a
(272.7)
74.0a,b
(352.6)
67.1a,b
(45.5)
480.0a
(356.1)
480.0a
(0.0)
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Figure 1. The time course of effects of the dopamine D2/D3 receptor agonist quinpirole on various HAL-induced maternal behavior deficits in
postpartum female rats. Pup retrieval (A), pup licking (B), nest building
(C) and pup nursing (D) were tested at baseline, 30, 60, 120 and 240 min
after injection of HAL or vehicle. HAL disrupted all the active maternal behaviors tested (A–C), but had no significant effect on pup nursing (D). Both 0.5 and 1.0 mg/kg of quinpirole improved the maternal behavior deficits induced by HAL in a dose-dependent fashion (A–C). Data
were represented as mean + SEM. * p < 0.05 versus VEH+VEH control; #
p < 0.05 versus VEH+HAL group.

Figure 2. The time course of effects of the 5-HT2A/2C receptor agonist
DOI on various HAL-induced maternal behavior deficits in postpartum female rats. Pup retrieval (A), pup licking (B), nest building (C)
and pup nursing (D) were tested at baseline, 30, 60, 120 and 240 min after injection of HAL or vehicle. HAL disrupted all the active maternal
behaviors tested (A–C), but had no significant effect on pup nursing
(D). Neither 1.0 nor 2.5 mg/kg of DOI rescued the HAL-induced deficits on active maternal behaviors (A–C), but 2.5 mg/kg of DOI further
suppressed nursing activity in HAL-treated dams (D). Data were represented as mean + SEM. * p < 0.05 versus VEH+VEH control; # p < 0.05
versus VEH+HAL group.

reached the normal level when the two QUI+HAL groups were
compared to the VEH+VEH control group (Figure 1B, p = 0.85 for
QUI-0.5+HAL group, p = 0.95 for QUI-1.0+HAL group).

ing time [F (4, 168) = 35.95, p < 0.001]. One-way ANOVA and post
hoc tests showed that the QUI-0.5+HAL group was significantly
different from the VEH+HAL group at the 120 and 240 min test
points (both ps = 0.021), whereas the QUI-1.0+HAL group differed
significantly from the VEH+HAL group at the 30, 120 and 240 min
test points post-injection (Figure 1C, all ps < 0.001). In particular,
although both doses of QUI reversed the disruptive effect of HAL
at the 120 min test point, only 1.0 mg/kg of QUI was capable of
improving it to the normal level when compared to the VEH+VEH
group (Figure 1C, p = 0.34).

3.1.2.4. Nest building. Similar to the effect on pup retrieval and
pup licking, both doses of QUI significantly improved the HALinduced disruption of nest building activity. Repeated measures
ANOVA revealed a significant interaction between the two factors
[F (20, 168) = 6.18, p < 0.001], a significant main effect of treatment
groups [F (5, 42) = 17.52, p < 0.001], and a significant effect of test-
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3.1.2.5. Pup nursing. As can be seen in Figure 1D, QUI pretreatment had no significant effect on pup nursing. Repeated
measures ANOVA revealed a significant interaction between the
two factors [F (20, 168) = 2.14, p = 0.005], a significant main effect of treatment groups [F (5, 42) = 4.66, p = 0.002], and a significant effect of testing time [F (4, 168) = 10.53, p < 0.001]. Post
hoc tests showed that both QUI groups were not significantly
different from the VEH+HAL group (both ps > 0.10).
3.1.3. DOI pretreatment failed to improve the haloperidol-induced
maternal behavior deficits
Both 1.0 and 2.5 mg/kg of DOI failed to improve the HAL-induced disruption on pup approach and pup retrieval, as evidenced by no significant improvement in the approach latency
nor in first and last pup retrieval latency (Table 1) when the
two DOI+HAL groups were compared to the VEH+HAL group.
Rather, 2.5 mg/kg of DOI further exacerbated the HAL-induced
disruption on the approach latency at the 60 min test point (Table 1, p = 0.005). Post hoc tests on the number of pups retrieved,
pup licking and nest building revealed that there was no significant difference between the two DOI+HAL groups and the
VEH+HAL group. For pup nursing, one-way ANOVA and post
hoc tests indicated that the DOI-2.5+HAL group showed an even
more suppressed nursing duration at the 30 and 120 min test
points compared to the VEH+HAL group (p = 0.048 for 30 min,
p = 0.041 for 120 min) (Figure 2D). The DOI-1.0+HAL group did
not differ significantly from the VEH+HAL group across the testing period.
3.2. Experiment 2. Effects of pretreatment with QUI or DOI
on clozapine-induced maternal behavior deficits
3.2.1. Clozapine treatment impaired various components of
maternal behavior
Consistent with our previous findings (Li et al., 2004; Zhao and
Li, 2009), the present study showed that a single injection of
CLZ significantly disrupted various active components of maternal behavior and maintained such a disruptive effect for about
2 h. In comparison with the vehicle-treated ones, rats treated
with CLZ took a much longer time to approach and retrieve their
first pups into the nest sites (Table 2) at the 30, 60 and 120 min
test points (0.001 < all ps < 0.01) and took longer to bring the last
pups into the nest with less pups retrieved across the testing period (Table 2, Figure 3 & Figure 4A) (0.001 < all ps < 0.05). They
also spent less time on pup licking, nest building and pup nursing at the 30, 60 and 120 min test points ( Figure 3 and Figure
4B,C,D) (all ps < 0.05).
3.2.2. QUI pretreatment failed to improve the clozapine-induced
maternal behavior deficits
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In contrast to its effects on HAL-induced maternal behavior deficits, both doses of QUI had little effect on the CLZ-induced disruptions of pup approach, pup retrieval latency (Table 2), the
number of pups retrieved and nest building (Figure 3A,C). Contrarily, QUI further potentiated the disruptive effect on these behaviors (Table 2, Figure 3A,C). Repeated measures ANOVA on the
number of pups retrieved and nest building revealed a significant
interaction between the treatment groups and test time points
[the number of pups retrieved:F (20, 168) = 9.56, p < 0.001; nest
building: F (20, 168) =2.77, p < 0.001], a significant main effect of
treatment groups [the number of pups retrieved: F (5, 42) = 20.41,
p < 0.001; nest building: F (5, 42) =13.61, p < 0.001], and a significant effect of test time points [the number of pups retrieved:F (4,
168) = 61.43, p < 0.001; nest building: F (4, 168) =38.33, p < 0.001].
One-way ANOVA and post hoc tests showed that the QUI1.0+CLZ group differed significantly from the VEH+CLZ group in
the number of pups retrieved and the duration of nest building
at the 240 min test point (Figure 3A,C, p = 0.001 for the number
of pups retrieved, p = 0.007 for the nest building), while the QUI0.5+CLZ group differed from the VEH+CLZ group in nest building
at the 240 min test point (Figure 3C, p = 0.026). QUI pretreatment
also did not improve the CLZ-induced deficits in pup licking and
pup nursing activities (Figure 3B,D) at any test points. Repeated
measures ANOVA on pup licking and pup nursing revealed a significant interaction between the two factors [pup licking:F (20,
168) = 1.68, p = 0.04; pup nursing: F (20, 168) = 2.05, p = 0.007],
a significant main effect of treatment groups [pup licking: F (5,
42) = 4.47, p = 0.002; pup nursing: F (5, 42) = 5.52, p = 0.001], and
a significant effect of test time points [pup licking:F (4, 168) =8.02,
p < 0.001; pup nursing: F (4, 168) = 6.72, p < 0.001]. Post hoc tests
on pup licking and pup nursing revealed that there was no significant difference between the two QUI+CLZ groups and the
VEH+CLZ group.
3.2.3. DOI pretreatment dose-dependently reversed the clozapineinduced maternal behavior deficits
As shown in Table 2 and Figure 4A,B, pretreatment of both doses
of DOI (1.0 and 2.5 mg/kg) significantly improved the CLZ-induced disruption on pup approach, pup retrieval, and pup licking. However, the reversing effect of DOI on CLZ-induced disruption of nest building and pup nursing was not apparent
(Figure 4C,D).
3.2.3.1. Latency to approach and retrieve pups. As shown in
Table 2, both 1.0 and 2.5 mg/kg of DOI shortened the prolonged
approach latency induced by CLZ when the two DOI+CLZ
groups were compared to the VEH+CLZ group and restored it to
the normal level compared to the VEH+VEH group at the 30, 60
and 120 min test points (0.001 < all ps < 0.01). It also reduced the
CLZ-induced deficits of the first pup retrieval and restored it to

Table 2. Effects of pretreatment with quinpirole or DOI on pup approach latency and pup retrieval latency in postpartum female rats treated with clozapine or vehicle.
Groups

N

Approach latency (s) 			

First pup retrieval latency (s) 		

Last pup retrieval latency (s)

		

Baseline 30 min

60 min

120 min 240 min Baseline 30 min

60 min

120 min 240 min Baseline 30 min

60 min

120 min 240 min

VEH+VEH
8
		
VEH+CLZ
8
		
QUI-0.5+CLZ 8
		
QUI-1.0+CLZ 8
		
DOI-1.0+CLZ 8
		
DOI-2.5+CLZ 8
		

2.1
(2.0)
1.8
(1.7)
8.7
(16.2)
5.3
(9.1)
2.2
(1.1)
1.6
(2.6)

1.5
(1.2)
290.8a
(474.6)
302.9a
(330.3)
129.0a
(240.4)
1.8b
(24.5)
1.3b
(7.2)

1.5
(0.8)
21.8a
(477.2)
268.2a
(432.7)
319.3a
(464.0)
1.7b
(1.2)
1.3b
(34.6)

2.6
(1.4)
480.0a
(0.0)
480.0a
(0.0)
480.0a
(0.0)
2.8b
(358.7)
2.5b
(63.4)

2.1
(0.7)
480.0a
(346.9)
480.0a
(0.0)
480.0a
(0.0)
3.4
(441.4)
2.4b
(34.8)

23.9
(7.7)
480.0a
(0.0)
480.0a
(0.0)
480.0a
(0.0)
58.3b
(453.3)
56.93b
(372.2)

21.7
(9.8)
480.0a
(0.0)
480.0a
$(0.0)
480.0a
(0.0)
214.7b
(452.0)
45.13b
(104.7)

1.2
(0.7)
68.5a
(357.3)
177.2a
(473.2)
159.9a
(460.3)
6.9b
(38.4)
1.8b
(0.4)

1.9
(4.6)
10.2
(43.7)
3.7
(7.6)
401.4a,b
(442.5)
2.2
(5.3)
1.8
(4.9)

2.8
(87.0)
5.9
(10.4)
14.3
(20.6)
10.4
(75.1)
7.7
(168.0)
2.7
(1.7)

2.0
(0.9)
480.0a
(357.1)
480.0a
(0.0)
480.0a
(0.0)
8.0a
(363.1)
21.8a
(371.5)

Data are represented as median ± interquartile range.
a. p < 0.05 relative to the VEH+VEH group; b. p < 0.05 relative to the VEH+CLZ group.

1.9
38.3
(0.5)
(104.0)
13.0
40.8
(154.8) (130.8)
480.0a,b 65.7
(339.1) (146.3)
480.0a,b 143.4
(0.0)
(408.2)
3.2
107.3
(360.7) (442.8)
2.2
37.13
(3.8)
(32.0)

22.6
(9.7)
480.0a
(0.0)
480.0a
(0.0)
480.0a
(0.0)
391.4a
(440.3)
480.0a
(396.9)

24.0
(14.4)
115.4a
(420.6)
480.0a
(0.0)
480.0a
(0.0)
44.8
(456.8)
34.4b
(54.7)
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Figure 3. The time course of effects of the dopamine D2/D3 receptor agonist quinpirole on various CLZ-induced maternal behavior deficits in
postpartum female rats. Pup retrieval (A), pup licking (B), nest building
(C) and pup nursing (D) were tested at baseline, 30, 60, 120 and 240 min
after injection of CLZ or vehicle. CLZ disrupted all maternal behaviors
tested (A–D). Both doses of quinpirole (0.5 and 1.0 mg/kg) failed to improve the maternal behavior deficits induced by CLZ (A–D), but rather
worsened pup retrieval (A) and nest building (C) deficits. Data were represented as mean + SEM. * p < 0.05 versus VEH+VEH control; # p < 0.05
versus VEH+CLZ group.

Figure 4. The time course of effects of the 5-HT2A/2C receptor agonist
DOI on various CLZ-induced maternal behavior deficits in postpartum
female rats. Pup retrieval (A), pup licking (B), nest building (C) and pup
nursing (D) were tested at baseline, 30, 60, 120 and 240 min after injection of CLZ or vehicle. CLZ disrupted all maternal behaviors tested (A–
D). Both doses of DOI (1.0 and 2.5 mg/kg) significantly improved the
pup retrieval and pup licking deficits induced by CLZ (A, B). However,
DOI did not improve the CLZ-induced disruption on nest building and
pup nursing (C, D). Data were represented as mean + SEM. * p < 0.05
versus VEH+VEH control; # p < 0.05 versus VEH+CLZ group.

the normal level at the 60 min test point (p = 0.035) at a dose
of 1.0 mg/kg as well as at the 60 and 120 min test points (both
ps < 0.01) at a dose of 2.5 mg/kg. For the last pup retrieval latency, both doses of DOI completely rescued the disruption at
the 60 and 120 min (0.001 < all ps < 0.01) test points. Furthermore, 2.5 mg/kg of DOI shortened the last pup retrieval latency
at the 240 min test point (p = 0.001).

3.2.3.2. Number of pups retrieved. Both doses of DOI increased the number of pups retrieved in the CLZ-treated rats.
One-way ANOVA and post hoc tests showed that there was a
significant difference between the DOI-1.0+CLZ group and the
VEH+CLZ group at the 60 and 120 min test points (p = 0.006
for 60 min, p = 0.008 for 120 min), whereas the DOI-2.5+CLZ
group differed significantly from the VEH+CLZ group even at
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the 240 min test point (Figure 4A, 0.001 < all ps < 0.05). Further analysis showed that the reversing effect of 1.0 mg/kg of
DOI reached the normal level at the 60 and 120 min test points
while the 2.5 mg/kg of DOI restored the CLZ-induced disruption
to the normal level at 60, 120 and 240 min test points (Figure 4A,
all ps > 0.05). It appears that the strongest reversal effect of DOI
occurred 120 min after CLZ administration (Figure 4A).
3.2.3.3. Pup licking. Both doses of DOI alleviated the CLZ-induced disruption on pup licking. One-way ANOVA and post hoc
tests showed that there was a significant difference between the
DOI-1.0+CLZ group and the VEH+CLZ group at the 120 min test
point (p = 0.049), while the DOI-2.5+CLZ group differed significantly from the VEH+CLZ group at the 60 and 120 min test
points (Figure 4B, p = 0.034 for 60 min, p = 0.015 for 60 min).
Further analysis showed that only 2.5 mg/kg of DOI restored
this behavior to the normal level at the 60 and 120 min test
points when the two DOI+CLZ groups were compared with the
VEH+VEH control group (Figure 4B, both ps > 0.05).
3.2.3.4. Nest building and pup nursing. Compared to the reversing effects on pup retrieval and pup licking, DOI at the currently tested doses appeared to be ineffective in reversing the
CLZ-induced deficits on nest building and pup nursing. Post hoc
tests on nest building and pup nursing revealed that there was
no significant difference between the two DOI+CLZ groups and
the VEH+CLZ group (Figure 4C,D, all ps > 0.05).
4. Discussion
The present study demonstrates an interesting double dissociation between dopamine and serotonin receptor mechanisms in
the mediation of HAL- and CLZ-induced maternal behavior deficits in postpartum rats. Acute treatment of HAL and CLZ disrupted various components of rat maternal behavior. Pretreatment of QUI, a selective D2/D3 dopaminergic receptor agonist,
but not DOI, a selective 5-HT2A/2C serotonergic receptor agonist,
dose-dependently improved HAL-induced disruption of pup approach, pup retrieval, pup licking and nest building, whereas
pretreatment of DOI, but not QUI, dose-dependently improved
CLZ-induced disruption of pup approach, pup retrieval and pup
licking. These data strongly suggest that the HAL-induced maternal deficits are primarily mediated by its blockade of D2 dopamine receptors, whereas the CLZ-induced maternal deficits are
primarily mediated by the blockade of 5-HT2A/2C receptors.
The dopamine systems have been well documented to play
an important role in the regulation of maternal behavior. For example, systemic (e.g., haloperidol, a D2 antagonist) or microinfusion of dopamine receptor antagonists such as SCH-23390 (a
D1 antagonist), pimozide (a D2 antagonist) and cis-flupenthixol
(a mixed D1/D2 antagonist) into the specific brain regions implicated in maternal behavior (e.g., medial preoptic area, nucleus
accumbens) disrupts various active maternal behaviors (Byrnes
et al., 2002; Giordano et al., 1990; Keer and Stern, 1999; Li et al.,
2004; Miller and Lonstein, 2005; Numan et al., 2005; Numan and
Stolzenberg, 2009; Silva et al., 2001, 2003; Stern and Taylor, 1991).
6-OHDA lesion of the ventral striatum and ventral tegmental
area disrupts pup retrieval (Hansen, 1994; Hansen et al., 1991a,
1991b). Additionally, mother–pup separation, which putatively
enhances maternal motivation (Hansen, 1994), stimulates dopamine release in the ventral striatum of maternal rats (Hansen
et al., 1993). Because HAL is primarily a D2 receptor antagonist,
we hypothesized that it disrupts maternal behavior by blocking D2 dopamine receptors. We tested this hypothesis by co-administrating QUI, a selective D2/D3 agonist together with HAL
and examined whether QUI could reverse the effects of HAL. As
expected, QUI did significantly improve the HAL-induced maternal behavior deficits. HAL rats pretreated with QUI showed
shortened pup approach and retrieval latency than those pre-
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treated with vehicle. This result is in general agreement with a
previous study showing that apomorphine, a mixed D1/D2 receptor agonist with a preferential affinity and potency for the D2
over D1 receptor subtype (Kebabian and Calne, 1979), reversed
HAL-induced pup retrieval deficits in postpartum rats (Giordano et al., 1990). We extended this line of research by showing
that HAL specifically acts on D2 receptors to achieve its disruptive effect. Of note, this finding does not necessarily rule out the
involvement of the D1 receptor mechanism because HAL does
have a weak D1 antagonism (Miyamoto et al., 2005), and other
studies also find that D1 receptors are involved in the regulation
of maternal behavior (Miller and Lonstein, 2005; Numan et al.,
2005; Numan and Stolzenberg, 2009).
The lack of the effect of DOI treatment on HAL-induced
maternal behavior deficits is not surprising given the fact that
DOI is a selective 5-HT2A/2C agonist and HAL lacks an action
on these serotonergic receptor systems. Interestingly, DOI pretreatment further decreased the duration of pup nursing in the
HAL-treated rats (see Figure 2D). Informal observations indicate that after the pups were returned to the cage, the HAL rats
pretreated with 2.5 mg/kg of DOI did not approach and retrieve
their pups, but stayed in the corner of the cage with no apparent movement. This may explain the reduction of pup nursing by DOI. In light that DOI itself reduces locomotor activity
(Hameleers et al., 2007; Krebs-Thomson and Geyer, 1996; Mittman and Geyer, 1991; Wing et al., 1990), it is possible that DOIinduced hypolocomotor activity may have contributed to its
disruptive effect on pup nursing.
Our original hypothesis that QUI may also attenuate the
CLZ-induced disruption to some extent, as CLZ also possesses
a D2 antagonism, was not supported by the present findings. In
contrast, QUI actually worsened some maternal behavior deficits, such as on pup retrieval and nest building. These findings
indicate that CLZ-induced maternal deficits are not primarily
mediated by its weak antagonism of D2 receptor. Our preliminary work (data not shown) finds that QUI at a dose of 1.0 mg/
kg by itself disrupts pup retrieval and nest building. Therefore, it
is possible that a combination of clozapine and QUI may provide
an additive disruption on the CLZ-induced maternal deficits.
The most striking finding from the present study was that
DOI pretreatment rescued most, if not all, maternal behavior
deficits induced by CLZ. We found that CLZ rats pretreated with
DOI took a much shorter time to initiate contact with pups and
retrieve their pups into the nest sites (Table 2), retrieved more
pups (Figure 4A) and spent more time licking their pups than
CLZ rats pretreated with vehicle (Figure 4B). CLZ has a unique
and multifaceted pharmacological, behavioral and clinical profile in comparison with other antipsychotic drugs (Matsubara et
al., 1993; Meltzer, 1989; Safferman et al., 1991; Schmauss et al.,
1989) due to its multiple-receptor action, including a relatively
high affinity for D4, histaminergic (H1), muscarinic, serotoninergic (5-HT2) and alpha-1-adrenergic receptors (Baldessarini et al.,
1992; Lane et al., 1988; Meltzer, 1989; Meltzer et al., 1989a; Miller
and Hiley, 1974; Seeman, 1992; Zavitsanou et al., 2007), moderate affinity for D1, D2, D5, alpha-2-adrenergic and 5-HT3 receptors (Ellenbroek et al., 1991; Matsubara et al., 1993; Miyamoto et
al., 2005; Murray and Waddington, 1990; Perry et al., 1983; Remington and Kapur, 2000). The unique antipsychotic property of
CLZ (e.g., low EPS and less prolactin elevation) has been correlated with its low affinity and fast dissociation at the D2 receptor (Kapur and Remington, 2001; Kapur and Seeman, 2001; Seeman, 2002). This profile makes it difficult to pinpoint the exact
mechanisms mediating the antipsychotic and behavioral effects
of CLZ. Our finding that DOI dose-dependently improved the
CLZ-induced maternal behavior deficits suggests that CLZ exerts
its disruptive effect on maternal behavior through a 5-HT2A/2C
receptor-mediated mechanism, and that this effect thus might
not be directly related to its antipsychotic efficacy, which is mediated by blockade of D2 receptors (Seeman, 2002).
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There are several possible mechanisms underlying the reversing effect of DOI on CLZ-induced maternal behavior deficits. First, DOI may directly activate the 5-HT2A/2C receptors localized in the brain regions important for maternal behavior,
such as the nucleus accumbens (NA) and the ventral tegmental
area (VTA), etc. There is considerable evidence demonstrating
that moderate to high levels of 5-HT2A/2C receptor immunoreactivity (Bubar et al., 2005; Clemett et al., 2000; Cornea-Hébert et
al., 1999; Jakab and Goldman-Rakic, 1998) and mRNAs (EberleWang et al., 1997; Pompeiano et al., 1994; Wright et al., 1995) are
expressed in the NA and VTA, thus, DOI may antagonize CLZ’s
blockade on 5-HT2A/2C receptors through competitive binding to
5-HT receptors in these areas to alleviate the CLZ-induced maternal behavior deficits.
Second, DOI may improve CLZ-induced maternal deficits
through its indirect action on the dopaminergic systems. The
mesolimbic dopamine system, originating in the VTA and terminating in the NA has been implicated in the appetitive aspects of maternal behavior (Hansen, 1994; Hansen et al., 1991a,
1991b; Hansen et al., 1993; Numan, 2007; Numan et al., 2005).
Recently, 5-HT2A/2C receptors were found to be localized on the
dopamine neurons in the VTA (Bubar and Cunningham, 2007;
Doherty and Pickel, 2000; Ji et al., 2006; Nocjar et al., 2002).
This finding provides evidence in support of the possible interaction between the serotonin and dopamine systems in the VTA
(Alex and Pehek, 2007; Di Matteo et al., 2001). More importantly,
a growing body of evidence shows that 5-HT2 receptors play a
prominent role in the modulation of mesolimbic dopamine-mediated function. For example, in the NA, activation of 5-HT2 receptor appears to facilitate dopamine release that can be blocked
by local injection of a 5-HT2 receptor antagonist (Parsons and
Justice, 1993). DOI, a mixed 5-HT2A/2C agonist, has been shown
to increase extracellular levels of dopamine in the posterior NA
(Bowers et al., 2000). Thus, it is possible that DOI may reverse
the effect of CLZ by regulating the DA release in the NA and thus
indirectly regulate maternal behavior via the DA system. Future
research should directly address the neural pathways that mediate the modulatory effects of 5-HT2A/2C receptors on the mesolimbic dopamine systems.
Third, at the behavioral level, the diminished sedation could
be a contributing factor in reversing CLZ-induced maternal deficits by DOI. In the present study, we noted that DOI treatment
significantly alleviated CLZ-induced sedative effect as those rats
showed increased motor activity, no sign of closed eyes or bowed
head. It has been reported that acute and repeated injection of
CLZ at a dose of 10.0 mg/kg produces substantial sedation in animals (Chesler and Salamone, 1996). The CLZ-induced sedative
effect has also been reported in the clinic (Burke and Sebastian,
1993; Safferman et al., 1991). Moreover, recent work from our laboratory shows that the sedative effect of CLZ contributes to its
disruption on maternal behavior (Zhao and Li, 2009). At this
point, it is still premature to suggest that DOI reverses CLZ’s disruption on maternal behavior by alleviating the sedative effect
of CLZ, because CLZ is not known to cause sedation by blocking 5-HT2A/2C receptors, but rather by blocking alpha-adrenergic and histamine receptors (Lieberman et al., 1989; Safferman et
al., 1991). More research is needed to examine whether CLZ can
cause sedation via action on 5-HT2A/2C receptors.
Because improvement of CLZ-induced disruption of nest rebuilding was not apparently observed after DOI pretreatment, it
is possible that other neurotransmitter systems may be involved
in CLZ-induced nest building deficit. One such system could involve the dopamine D2/D3 receptors, as our results show that
HAL-induced disruption of nest building was reversed and restored to the normal level by QUI, a selective D2/D3 receptor agonist. Other systems may include dopamine D1, D4 and D5 receptors. CLZ has high affinity for D4 and moderate affinity for

D1 and D5 receptors. Consistent with this hypothesis, previous
studies have shown that D1 receptor activity is critical for the regulation of maternal behavior. Microinjection of a dopamine D1
receptor antagonist SCH-23390 into the medial preoptic area
(MPOA) or nucleus accumbens (NA) greatly impairs pup retrieval in postpartum rats (Miller and Lonstein, 2005; Numan et
al., 2005). Microinfusion of a dopamine D1 receptor agonist SKF38393 into either the MPOA or the NA promotes the onset of
maternal behavior in pregnancy-terminated rats (Stolzenberg et
al., 2007). However, it is unknown whether the D4 and/or D5 receptors are involved in the regulation of maternal behavior due
to lack of evidence. Alternatively, nest building activity may still
be mediated by 5-HT2A/2C receptors, but is more sensitive and
vulnerable to pharmacological intervention (Li et al., 2004; Silva
et al., 2001; Zhao and Li, 2009). Future work should address this
issue in detail.
The present study provides strong evidence supporting the
involvement of 5-HT2A/2C receptors in the mediation of rat maternal behavior. Previous work on this issue is inadequate and
inconsistent. For example, Brunner et al. (1999) reported that
5-HT1B receptor knockout mother mice did not display pup retrieval deficits. More recently, Lerch-Haner et al. (2008) reported
that transgenic mouse dams with a specific disruption in serotonin neuron development displayed profound maternal deficits
(e.g., pup retrieval, pup nursing, nest building). This study, however, did not answer which subtypes of 5-HT receptor are implicated in maternal activity. Other studies have found that 5-HT1B
and 5-HT2A/2C receptors are involved in maternal aggressive behavior (De Almeida et al., 2005, 2006a, 2006b; Olivier et al.,
1995; Veiga et al., 2007). For example, intracerebroventricular injections of DOI, a 5-HT2A/2C agonist, inhibited maternal aggression in postpartum female rats (De Almeida and Lucion, 1994).
To the best of our knowledge, the present study was the first to
demonstrate that 5-HT2A/2C receptors may be important in regulating rat maternal behavior.
Consistent with our previous work (Li et al., 2004), we
found that HAL and CLZ had different time courses of action.
HAL tended to produce a prolonged disruption, whereas CLZ
produced a transient one. For instance, the HAL-induced disruption of nest building was still apparent even at the 240 min
test point (4 h post-injection), whereas the effect of CLZ was
diminished (Figure 1 & Figure 3, C). It appears that the reversal
effect of QUI on HAL-induced maternal deficits also differed
in regard to time course of action from that of DOI on CLZ-induced deficits. For example, the reversal effect of DOI on CLZinduced disruption of pup retrieval was somewhat delayed in
onset when compared to that of quinpirole on HAL-induced
impairment (Figure 1 & Figure 4 A), which may be attributable
to the rapid peak plasma concentration of quinpirole (Whitaker and Lindstrom, 1987).
Taken together, the present study demonstrates an interesting double dissociation receptor mechanism underlying the
HAL and CLZ-induced maternal behavior deficits. Our data suggest that the HAL-induced maternal deficits are primarily mediated by the blockade of D2 dopamine receptors, whereas the
CLZ-induced maternal deficits are primarily mediated by the
blockade of 5-HT2A/2C receptors. Because not all components of
CLZ-induced maternal behavior deficits were reversed by DOI,
other receptor mechanisms such as the D1 receptor may also be
involved, prompting the need for further investigation.
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